ArticleJournal of evidence-based medicine2026
Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross-Sectional Study.
Article in Journal of evidence-based medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveClinical trials are regarded as an essential method for developing new treatments and giving patients access to potentially effective medications that are still being studied. This study aimed to evaluate acceptance of participating in clinical trials of new drugs and to further explore the associated factors.
methodsA population-based cross-sectional study was conducted in China from June 20 to August 31, 2022. We collected demographic data and used visual analog scale scores to assess the public's willingness to accept clinical trials of new drugs (range 0-100). Linear regression analysis was adopted to evaluate the factors related to attitudes toward clinical trials of new drugs.
resultsThis survey contained 19,710 valid questionnaires to investigate acceptance of participating in clinical trials of new drugs. Participants showed low willingness to accept clinical trials of new drugs, with a mean score of 44.69 out of 100. The results showed that rural residence (β = 3.00), western China (β = 3.15), being married (β = 2.93), older age (31-59 years [β = 3.84], ≥60 years [β = 7.71]), having cancer or rare diseases (β = 5.15), higher monthly household income (>6000 yuan [β = 1.76]), medical-related occupations (β = 8.01), anxiety status (moderate anxiety [β = 1.83]), moderate to severe anxiety [β = 2.66]), perceived stress (β = 0.51), health literacy (β = 0.21), self-efficacy (β = 0.34), and media use (β = 0.42) were associated with higher acceptance of participating in clinical trials of new drugs. However, central China (β = -1.65), female sex (β = -2.29), chronic diseases (β = -2.45), and medical insurance (β = -3.78) were associated with lower acceptance of participating in clinical trials of new drugs. Subgroup analysis demonstrated consistent trends across age and chronic disease subgroups.
conclusionsThis reveales low public willingness to accept clinical trials of new drugs. The willingness is affected by marital status, occupation, area of residence, income, health insurance, physical and mental health status, media use, and health literacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.